BHCM
KPTI icon

Brevan Howard Capital Management’s Karyopharm Therapeutics KPTI Stock Holding History

Brevan Howard Capital Management’s Portfolio KPTI Stock Details KPTI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.03M Buy
309,817
+97,450
+46% +$845K 0.02% 544
2026
Q1 		$1.18M Buy
+212,367
New +$1.62M 0.01% 823
2023
Q4 		– Sell
-1,522
Closed -$30.6K – 1060
2023
Q3 		$30.6K Buy
+1,522
New +$34.2K ﹤0.01% 375

Other funds holding KPTI

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
ACA
Acorn Capital Advisors New York $366M AUM 474.6% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
CCM
Catalio Capital Management New York $532M AUM 171.17% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $624M AUM 250.2% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Brevan Howard Capital Management's KPTI Position: Q2 2026 in Review

Brevan Howard Capital Management increased its Karyopharm Therapeutics (KPTI) stake by 46% in Q2 2026, buying an estimated $845K and bringing the position to 309,817 shares worth $3.03M. The position accounts for 0.02% of the portfolio, ranked #544.

Brevan Howard Capital Management first reported a position in KPTI in Q3 2023 and has held it in 3 quarters since. 97 funds tracked by Wall St. Rank hold KPTI as of Q2 2026.

  • Brevan Howard Capital Management held 309,817 shares of Karyopharm Therapeutics worth $3.03M as of Q2 2026.
  • Brevan Howard Capital Management bought 97,450 Karyopharm Therapeutics shares in Q2 2026, an estimated $845K.
  • Karyopharm Therapeutics made up 0.02% of Brevan Howard Capital Management's portfolio in Q2 2026, its #544 holding.
  • Brevan Howard Capital Management first reported a position in Karyopharm Therapeutics in Q3 2023 and has held it in 3 quarters since.
  • 97 funds tracked by Wall St. Rank held Karyopharm Therapeutics as of Q2 2026.

Based on Brevan Howard Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.